217 related articles for article (PubMed ID: 7486902)
1. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.
Nguyen MH; Barchiesi F; McGough DA; Yu VL; Rinaldi MG
Antimicrob Agents Chemother; 1995 Aug; 39(8):1691-5. PubMed ID: 7486902
[TBL] [Abstract][Full Text] [Related]
2. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
[TBL] [Abstract][Full Text] [Related]
3. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
[TBL] [Abstract][Full Text] [Related]
4. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
5. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
8. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2003 Oct; 47(10):3361-4. PubMed ID: 14506059
[TBL] [Abstract][Full Text] [Related]
9. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.
Barchiesi F; Gallo D; Caselli F; Di Francesco LF; Arzeni D; Giacometti A; Scalise G
J Antimicrob Chemother; 1999 Jul; 44(1):65-70. PubMed ID: 10459811
[TBL] [Abstract][Full Text] [Related]
10. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
11. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Larsen RA; Bauer M; Thomas AM; Graybill JR
Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793
[TBL] [Abstract][Full Text] [Related]
13. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Vu K; Gelli A
Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
[TBL] [Abstract][Full Text] [Related]
14. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Najvar LK; Bocanegra R; Caselli F; Di Cesare S; Giannini D; Di Francesco LF; Giacometti A; Carle F; Scalise G; Graybill JR
Antimicrob Agents Chemother; 2001 May; 45(5):1355-9. PubMed ID: 11302795
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
16. Cryptococcus neoformans: the model organism for yeast antifungal drug susceptibility testing.
Bauer M; Thomas AM; Larsen RA
Mycopathologia; 2012 Jun; 173(5-6):435-43. PubMed ID: 22322619
[TBL] [Abstract][Full Text] [Related]
17. Comparison of broth dilution and semisolid agar dilution for in vitro susceptibility testing of Cryptococcus neoformans.
Del Poeta M; Barchiesi F; Morbiducci V; Arzeni D; Marinucci G; Ancarani F; Scalise G
J Chemother; 1994 Jun; 6(3):173-6. PubMed ID: 7983499
[TBL] [Abstract][Full Text] [Related]
18. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans.
Ghannoum MA; Fu Y; Ibrahim AS; Mortara LA; Shafiq MC; Edwards JE; Criddle RS
Antimicrob Agents Chemother; 1995 Nov; 39(11):2459-65. PubMed ID: 8585726
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
